BIOMAT Database Logo BIOMAT Database Logo

Purification and characterization of a variant of human prothrombin: prothrombin Segovia. 1997

M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Laboratory of Vascular Biology and Thrombosis Research, School of Medicine, University of Navarra, Pamplona, Spain.

A dysprothrombin designated prothrombin Segovia was isolated from the plasma of an individual with normal prothrombin antigen and prothrombin activity lesser than 25% of the control prothrombin activity. Activation by prothrombinase complex showed a lower amidolytic than clotting activity, which suggests a lesser generation of active intermediates than normal prothrombin. When prothrombin Segovia was activated by prothrombinase complex in the absence of factor Va, no thrombin formation was found by functional activities. SDS-PAGE analysis of the molecules derived by activation with prothrombinase complex, Taipan snake venom and Echis carinatus venom showed an accumulation of molecules not cleaved at bond Arg320-Ile321. This was more evident with Echis carinatus venom, which only acts on this bond. Our data suggest that the alteration of prothrombin Segovia impairs the scission of bond Arg320-Ile321.

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D010450 Endopeptidases A subclass of PEPTIDE HYDROLASES that catalyze the internal cleavage of PEPTIDES or PROTEINS. Endopeptidase,Peptide Peptidohydrolases
D011516 Prothrombin A plasma protein that is the inactive precursor of thrombin. It is converted to thrombin by a prothrombin activator complex consisting of factor Xa, factor V, phospholipid, and calcium ions. Deficiency of prothrombin leads to hypoprothrombinemia. Coagulation Factor II,Factor II,Blood Coagulation Factor II,Differentiation Reversal Factor,Factor II, Coagulation,Factor, Differentiation Reversal,II, Coagulation Factor
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D004591 Electrophoresis, Polyacrylamide Gel Electrophoresis in which a polyacrylamide gel is used as the diffusion medium. Polyacrylamide Gel Electrophoresis,SDS-PAGE,Sodium Dodecyl Sulfate-PAGE,Gel Electrophoresis, Polyacrylamide,SDS PAGE,Sodium Dodecyl Sulfate PAGE,Sodium Dodecyl Sulfate-PAGEs
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005165 Factor V Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor V accomplishes this by forming a complex with factor Xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor V leads to Owren's disease. Coagulation Factor V,Proaccelerin,AC Globulin,Blood Coagulation Factor V,Factor 5,Factor Five,Factor Pi,Factor V, Coagulation
D005170 Factor X Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder. Autoprothrombin III,Coagulation Factor X,Stuart Factor,Stuart-Prower Factor,Blood Coagulation Factor X,Factor 10,Factor Ten,Stuart Prower Factor,Factor X, Coagulation
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Purification and partial characterization of a new variant of human prothrombin: prothrombin Metz.
December 1979, FEBS letters,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Characterization of a variant of human prothrombin: prothrombin Madrid.
January 1981, Annals of the New York Academy of Sciences,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Prothrombin Segovia: a new congenital abnormality of prothrombin.
May 1986, Scandinavian journal of haematology,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Isolation and partial characterization of a human prothrombin variant: prothrombin Barcelona.
October 1974, Biochemical and biophysical research communications,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Prothrombin Tokushima: characterization of dysfunctional thrombin derived from a variant of human prothrombin.
February 1987, Blood,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Prothrombin Poissy: a new variant of human prothrombin.
June 1987, British journal of haematology,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Purification and characterization of ostrich prothrombin.
January 2000, The international journal of biochemistry & cell biology,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Abnormal activation of a human prothrombin variant: prothrombin Barcelona.
March 1978, FEBS letters,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Gly319 --> arg substitution in the dysfunctional prothrombin Segovia.
June 1999, British journal of haematology,
M T Collados, and J Fernández, and J A Páramo, and R Montes, and J R Borbolla, and L F Montaño, and E Rocha
Sheep prothrombin: purification and partial characterization.
December 1976, Biochimica et biophysica acta,
Copied contents to your clipboard!